GSA Capital Partners’s Arcus Biosciences RCUS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $948K | Sell |
116,461
-79,790
| -41% | -$649K | 0.07% | 490 |
|
|
2025
Q1 | $1.54M | Buy |
196,251
+124,701
| +174% | +$979K | 0.14% | 150 |
|
|
2024
Q4 | $1.07M | Sell |
71,550
-115,865
| -62% | -$1.72M | 0.08% | 368 |
|
|
2024
Q3 | $2.87M | Buy |
187,415
+28,307
| +18% | +$433K | 0.22% | 42 |
|
|
2024
Q2 | $2.42M | Buy |
+159,108
| New | +$2.42M | 0.17% | 95 |
|
|
2024
Q1 | – | Sell |
-90,873
| Closed | -$1.74M | – | 1905 |
|
|
2023
Q4 | $1.74M | Buy |
90,873
+69,735
| +330% | +$1.33M | 0.15% | 161 |
|
|
2023
Q3 | $379K | Buy |
+21,138
| New | +$379K | 0.03% | 957 |
|
|
2023
Q2 | – | Sell |
-20,886
| Closed | -$381K | – | 1872 |
|
|
2023
Q1 | $381K | Sell |
20,886
-9,222
| -31% | -$168K | 0.04% | 882 |
|
|
2022
Q4 | $623K | Buy |
+30,108
| New | +$623K | 0.08% | 465 |
|
|
2022
Q3 | – | Sell |
-9,888
| Closed | -$251K | – | 1803 |
|
|
2022
Q2 | $251K | Sell |
9,888
-5,921
| -37% | -$150K | 0.04% | 934 |
|
|
2022
Q1 | $499K | Buy |
15,809
+9,599
| +155% | +$303K | 0.07% | 535 |
|
|
2021
Q4 | $251K | Buy |
+6,210
| New | +$251K | 0.03% | 1067 |
|
|
2020
Q4 | – | Sell |
-31,217
| Closed | -$535K | – | 1528 |
|
|
2020
Q3 | $535K | Buy |
31,217
+21,800
| +231% | +$374K | 0.09% | 350 |
|
|
2020
Q2 | $233K | Sell |
9,417
-23,902
| -72% | -$591K | 0.13% | 272 |
|
|
2020
Q1 | $462K | Sell |
33,319
-37,300
| -53% | -$517K | 0.12% | 209 |
|
|
2019
Q4 | $713K | Buy |
70,619
+31,265
| +79% | +$316K | 0.08% | 412 |
|
|
2019
Q3 | $358K | Buy |
39,354
+23,111
| +142% | +$210K | 0.05% | 771 |
|
|
2019
Q2 | $129K | Buy |
16,243
+2,392
| +17% | +$19K | 0.01% | 1314 |
|
|
2019
Q1 | $173K | Buy |
+13,851
| New | +$173K | 0.02% | 1265 |
|